President Banjun Yang, President and CEO. Mr. Yang has more than 25 years of experience in entrepreneurial and investment management in Hong Kong, Beijing and Shanghai. He served as Chairman of the Board and General Manager for Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. from 1996 to 2006, and from 1991 to the present as Chairman of Hong Kong Wanxing Enterprises. In the 1990s, he was Chairman of Shanghai Wanxing Automobile Service Co. Ltd. and Beijing Automobile Service Co. Ltd. following service in senior positions in the late 1980s at the Shenzhen Beijing Hotel and at the Shenzhen Nabei Trade Centre.
Christopher Metcalf, Director; Chair of Audit Committee. Mr. Metcalf is an investment professional with experience in venture capital, investment banking, commercial banking and all aspects of financial analysis. He has served as Vice President of the Graystone Research Group of Morgan Stanley in New York, President of Altitude Funds LLC, Vice President of KMV Capital, and Vice President and Senior Financial Analyst with Charles Schwab’s Family office. Mr. Metcalf is a member of both the Virginia and California State Bar Associations. He received a BSc in Commerce and a Juris Doctor degree from the University of Virginia, and an MBA from the University of Chicago.
Zhong Zhuang, Vice General Manager. Mr. Zhuang trained as a medical doctor at the Second Military Medical School in Shanghai and practiced for five years before obtaining his MBA from Fudan University. He has served as Vice General Manager for Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. since 2002. Prior to that he was the Vice General Manager at United Gene Science and Technology in Shanghai and the Manager of Shanghai Likang Science Investment Enterprise.
Dr. Zhifang Cao, Deputy Vice General Manager. Dr. Cao integrates an extensive clinical background with a market-driven approach to identifying and developing bio-pharmaceuticals with strong therapeutic as well as profit potential. He joined the Company in 1999 and is responsible for planning and directing new drug development. A former Associate Professor and Director of Research and Development at Second Military Medical Hospital in Shanghai, Dr. Cao has more than 15 years of clinical experience, exceptional organizational ability and well-developed relationships in the bio-pharmaceutical industry. He earned his MD from Harbin University in 1984 and completed MBA studies at the Shanghai Cadre Training Center in 2001.
Xiudong Huang, Manager of Research and Development. Mr. Huang, a molecular biologist, has been involved in the development of some 15 recombinant protein drugs since 1998 and holds two Chinese patents, with another eight patents applied for. He joined the Company in 2001 to manage R&D, with responsibility for project selection, construction of host cells and new drug processing, including fermentation, purification and formulation steps. Prior to that he served as an associate professor in the Medical College of Anhui Science and Technology University, doing both research and teaching. He earned his Master’s Degree in Molecular Biology from the University of Science and Technology of China.
Mrs. Pan Xuegong, Quality Control Director. Mrs. Xuegong has more than 15 years of experience in pharmaceutical quality control. She joined the Company in 1999 and oversees the analysis, specification, quality control, application and registration of new drugs and bio-products using a series of assays and GMP processes that meet Chinese FDA requirements. She graduated from China Pharmaceutical University with a Bachelor Degree and obtained a Master’s Degree in Pharmacy at Shanghai Second Military Medical University.
Advisors and Consultants
Dr. Tom (Dwun-Hou) Chen, Chief Technical Consultant. Dr. Chen, Vice President of Process Development at Prometic BioTherapeutics in Rockville, Maryland, also serves as a consultant to the Program for Appropriate Technology in Health (PATH) in leading the process development and the manufacturing programs for SinoBiomed’s recombinant malaria vaccine. In addition to consulting for several private biotech companies, Dr. Chen has also served as the Director of Process Development for Plasma Derivatives for the American Red Cross. He obtained his BSc in Chemistry from Tamkang University, Taiwan, R.O.C., and his Ph.D. in Biochemistry from Auburn University.
Dr. Weiqing Pan, Advisor. Professor Dr. Pan, an internationally recognized researcher with more than 30 articles published in leading medical and scientific journals, heads the Department of Parasitology at the Second Military Medical University and serves on China’s national committee to combat parasitic diseases. Professor Pan is the inventor of the patented plasmodium fusion antigen that SinoBiomed is developing and testing as a blood-stage malaria vaccine with the support of the World Health Organization (WHO) and Program for the Appropriate Technology in Health (PATH). Professor Pan has won more than $2 million in research grants and is a frequent speaker at international conferences.
Jianzhi Xiang, Consultant. Mr. Xiang has been involved in the research, development and evaluation of bio-pharmaceutical and bio-products since 1961. He currently serves as a Panel Member of Expert Committee of Biological Standardization for the World Health Organization and has served as a consultant to public and private sector organizations, including Life Biotechnologies of Maryland and the Chinese Food and Drug Administration’s Center for Drug Evaluation. Mr. Jiang also has more than 30 years experience working as an investigator in biologicals, serving most recently as Principal Investigator and Chairman of the Expert Committee on Science and Technology, Shanghai Institute of Biological Products. He earned a Bachelor’s Degree in Chemistry from the University of Nanking in 1951.
Professor Yu-Yang Li, Advisor. Professor Li’s area of expertise is in foreign gene expression in yeast, a key element in the production process of SinoBiomed’s malaria vaccine. Professor Li conducts research in generic engineering and teaches molecular genetics and yeast genetic engineering at the Institute of Genetics of Fudan University in Shanghai. A former Dean of Fudan’s School of Life Sciences and Member of Expert Committee on the Field of Biotechnology of the National High-Tech Program in China, he continues to serve as a Drug Evaluation Expert for China’s State Drug Administration.
Dr. Dicken Shiu-Chung Ko, Advisor. Dr. Ko is an internationally recognized authority in kidney and pancreas transplantation. He is currently the Director of Adult Renal Transplantation at Massachusetts General Hospital, Assistant Professor of Surgery at Harvard Medical School and Chair of the Scientific Program of the Urological Society for Transplantation. A fellow of the American College of Surgeons, he has also received Specialty Board Certification in Urology from the Royal College of Physicians and Surgeons of Canada. He received a BSc from the University of British Columbia, an MD from Queen’s University and has undertaken postdoctoral training in surgery, urology, clinical transplantation and transplantation.
SinoBiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, SinoBiomed currently has 10 products approved or in development: two on the market, one awaiting approval, four in clinical trials and three in R&D. The Company’s products respond to a wide range of diseases, including cancer, malaria and hepatitis.
SinoBiomed’s combination of advanced technology and expertise enables the Company to produce safe, high-yield, high-efficacy recombinant protein drugs at extremely low cost. SinoBiomed employs a patented low-cost, high-yield production process to enhance bioactivity and guarantee the highest levels of purity.